PT3104872T - Paricalcitol para uso no tratamento de anemia inflamatória - Google Patents

Paricalcitol para uso no tratamento de anemia inflamatória

Info

Publication number
PT3104872T
PT3104872T PT15702156T PT15702156T PT3104872T PT 3104872 T PT3104872 T PT 3104872T PT 15702156 T PT15702156 T PT 15702156T PT 15702156 T PT15702156 T PT 15702156T PT 3104872 T PT3104872 T PT 3104872T
Authority
PT
Portugal
Prior art keywords
paricalcitol
treatment
inflammatory anaemia
anaemia
inflammatory
Prior art date
Application number
PT15702156T
Other languages
English (en)
Portuguese (pt)
Inventor
Giovanni Uriol Rivera Miguel
Original Assignee
Giovanni Uriol Rivera Miguel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giovanni Uriol Rivera Miguel filed Critical Giovanni Uriol Rivera Miguel
Publication of PT3104872T publication Critical patent/PT3104872T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT15702156T 2014-02-11 2015-01-16 Paricalcitol para uso no tratamento de anemia inflamatória PT3104872T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria

Publications (1)

Publication Number Publication Date
PT3104872T true PT3104872T (pt) 2019-06-11

Family

ID=51205045

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15702156T PT3104872T (pt) 2014-02-11 2015-01-16 Paricalcitol para uso no tratamento de anemia inflamatória

Country Status (16)

Country Link
US (1) US11464791B2 (enExample)
EP (1) EP3104872B1 (enExample)
JP (1) JP2017512753A (enExample)
KR (1) KR20160113664A (enExample)
CN (1) CN106061498B (enExample)
AR (1) AR099330A1 (enExample)
AU (1) AU2015217956B2 (enExample)
CA (1) CA2938057A1 (enExample)
DK (1) DK3104872T3 (enExample)
ES (2) ES2472040B1 (enExample)
IL (1) IL247207B (enExample)
MX (1) MX365096B (enExample)
PT (1) PT3104872T (enExample)
RU (1) RU2016131412A (enExample)
UY (1) UY35989A (enExample)
WO (1) WO2015121022A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102504090B1 (ko) * 2020-08-05 2023-02-24 경상국립대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583539A2 (en) 2003-01-13 2005-10-12 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
CN102772364B (zh) * 2011-05-13 2015-12-02 重庆华邦制药有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Also Published As

Publication number Publication date
ES2472040B1 (es) 2015-07-01
AU2015217956B2 (en) 2019-04-04
CN106061498B (zh) 2019-12-06
DK3104872T3 (da) 2019-06-17
AR099330A1 (es) 2016-07-13
ES2472040R1 (es) 2014-09-18
WO2015121022A1 (en) 2015-08-20
ES2472040A2 (es) 2014-06-27
EP3104872A1 (en) 2016-12-21
US20160367571A1 (en) 2016-12-22
EP3104872B1 (en) 2019-03-13
MX2016010104A (es) 2017-01-06
MX365096B (es) 2019-05-22
IL247207A0 (en) 2016-09-29
ES2728158T3 (es) 2019-10-22
RU2016131412A (ru) 2018-03-15
IL247207B (en) 2020-02-27
US11464791B2 (en) 2022-10-11
CN106061498A (zh) 2016-10-26
CA2938057A1 (en) 2015-08-20
JP2017512753A (ja) 2017-05-25
KR20160113664A (ko) 2016-09-30
AU2015217956A1 (en) 2016-08-25
UY35989A (es) 2015-03-27

Similar Documents

Publication Publication Date Title
IL251526A0 (en) Use of cannabidiol in the treatment of multiple sclerosis complex
EP3188741A4 (en) Compositions and methods for the treating an inflammatory disease or disorder
AP2017009674A0 (en) Methods and compositions for treating ulcers
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL251905A0 (en) Epilimod for use in the treatment of kidney cancer
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
EP3215157B8 (en) Apilimod for use in the treatment of melanoma
PT3331610T (pt) Agentes para utilização no tratamento de glioma
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
HUE044801T2 (hu) Adelmidrol alkalmazása epitheliális mûködési zavarok kezelésében
IL249152B (en) Botulinum toxin for use in the treatment of paratonia
GB2526391B (en) Improvements in or relating to expansion apparatus
GB201513543D0 (en) Compositions for use in the treatment of diabetes
IL247207B (en) Use of pericalcitol in the treatment of inflammatory anemia
ZA201408464B (en) Composition for the use in treatment of asthma
GB201407244D0 (en) Apparatus for use in the manufacture of glass items
GB201511772D0 (en) Improvements in the treatment of ash
GB201405898D0 (en) Dressing
GB201415122D0 (en) Apparatus for use in the fashion industry
GB201418134D0 (en) Bandage
GB201400621D0 (en) The assimilators reduction process